07:00 , Aug 4, 2008 |  BC Week In Review  |  Company News

Bio-Bridge, Xinheng Baide Biotechnology Co. Ltd. deal

Bio-Bridge completed its previously announced acquisition of a 51% stake in Xinheng for RMB6 million ($877,200) (see BioCentury, May 5). Bio-Bridge Science Inc. (OTCBB:BGES), Oak Brook, Ill.   Xinheng Baide Biotechnology Co. Ltd. , Huhot,...
07:00 , May 5, 2008 |  BC Week In Review  |  Company News

Bio-Bridge, Xinheng Baide Biotechnology Co. Ltd. deal

Bio-Bridge will acquire 51% of Xinheng, a bovine serum manufacturer, for RMB6 million ($865,000). The deal is expected to close in May. In November, Bio-Bridge acquired 51% of Lanzhou Roya Biotechnology Co. Ltd. (China), also...
08:00 , Nov 5, 2007 |  BC Week In Review  |  Company News

Bio-Bridge, Lanzhou Roya Biotechnology Co. Ltd. deal

BGES signed a non-binding letter of intent to acquire 51% of Lanzhou, a bovine serum manufacturer. BGES said the acquisition will enable it to build a distribution network in China and begin earning revenue. BGES...
07:00 , Apr 9, 2007 |  BC Week In Review  |  Company News

Bio-Bridge board of directors update

Bio-Bridge Science Inc. (BGES), Oak Brook, Ill.   Business: Infectious   Appointed: Trevor Roy, chairman and CEO of Creata Group; and Anthony Cheung  ...
07:00 , Jun 19, 2006 |  BC Week In Review  |  Clinical News

Bio-Bridge preclinical data

Data from a preclinical immunogenicity study in monkeys showed that BGES's oral HIV vaccine induces HIV-1 gp41-specific serum antibodies (IgG) and intestinal and vaginal antibodies (sIgA). Sera, intestinal, and vaginal washings were shown to neutralize...
08:00 , Feb 6, 2006 |  BC Week In Review  |  Clinical News

Bio-Bridge preclinical data

Researchers reported that low, medium and high doses of HIV pseudovirus (HIV-PV) vaccine did not have any side effects on the central nervous system, the cardiovascular system or the respiratory system of mice and monkeys....